Citigroup
BSPM

Citigroup’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History

Citigroup’s Portfolio BSPM Stock Details BSPM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-32
Closed – – 7504
2014
Q2 		$0 Buy
+32
New +$353 ﹤0.01% 7510
2014
Q1 		– Sell
-183
Closed -$3K – 7373
2013
Q4 		$3K Buy
+183
New +$1.98K ﹤0.01% 6746

Other funds holding BSPM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's BSPM Position: Q3 2014 in Review

Citigroup sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q3 2014, closing a stake of 32 shares.

Citigroup first reported a position in BSPM in Q4 2013 and held it in 2 quarters. The position peaked at $3K in Q4 2013. 11 funds tracked by Wall St. Rank hold BSPM as of Q3 2014.

  • Citigroup reported no remaining Biostar Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Citigroup sold 32 Biostar Pharmaceuticals, Inc. shares in Q3 2014.
  • Citigroup first reported a position in Biostar Pharmaceuticals, Inc. in Q4 2013 and held it in 2 quarters.
  • Citigroup's Biostar Pharmaceuticals, Inc. position peaked at $3K in Q4 2013.
  • 11 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q3 2014.

Based on Citigroup's 13F filing for Q3 2014, filed 14 Nov 2014.